{"pmid":32479893,"title":"Ivermectin: repurposing a multipurpose drug for Venezuela's humanitarian crisis.","text":["Ivermectin: repurposing a multipurpose drug for Venezuela's humanitarian crisis.","For decades, Ivermectin (IVM) has been recognized as a robust antiparasitic drug with excellent tolerance and safety profiles. Historically it has been used as the drug of choice for onchocerciasis and lymphatic filariasis global elimination programs. IVM is also a standard treatment against intestinal helminths and ectoparasites given its action as an oral insecticide. The current humanitarian crisis in Venezuela is a regional public health threat that requires immediate action. Venezuela's public health system has now crumbled due to a 70% shortage of medicines in public hospitals, low vaccination campaigns, and the massive exodus of medical personnel. Herein we discuss the repurposing of IVM to attenuate the burden imposed by the most prevalent neglected tropical diseases (NTDs) in Venezuela including soil-transmitted helminths, ectoparasites and, possibly, vector-borne diseases such as malaria. Additionally, novel experimental evidence has shown that IVM is active and efficacious against Chagas disease, Leishmaniases, arboviruses, and SARS-CoV-2 in vitro. In crisis-hit Venezuela, all of the aforementioned infectious diseases are public health emergencies that have been long ignored and that also require immediate attention. IVM's versatile nature could serve as a powerful tool to tackle the multiple overlapping endemic and emergent diseases that affect Venezuela today. The repurposing of this multipurpose drug would be without a doubt a timely therapeutical approach to help mitigate the tremendous burden of NTDs nationwide.","Int J Antimicrob Agents","Perez-Garcia, Luis A","Mejias-Carpio, Isis E","Delgado-Noguera, Lourdes A","Manzanarez-Motezuma, Jean P","Escalona-Rodriguez, Maria A","Sordillo, Emilia M","Mogollon-Rodriguez, Euler A","Hernandez-Pereira, Carlos E","Marquez-Colmenarez, Marilianna C","Paniz-Mondolfi, Alberto E","32479893"],"abstract":["For decades, Ivermectin (IVM) has been recognized as a robust antiparasitic drug with excellent tolerance and safety profiles. Historically it has been used as the drug of choice for onchocerciasis and lymphatic filariasis global elimination programs. IVM is also a standard treatment against intestinal helminths and ectoparasites given its action as an oral insecticide. The current humanitarian crisis in Venezuela is a regional public health threat that requires immediate action. Venezuela's public health system has now crumbled due to a 70% shortage of medicines in public hospitals, low vaccination campaigns, and the massive exodus of medical personnel. Herein we discuss the repurposing of IVM to attenuate the burden imposed by the most prevalent neglected tropical diseases (NTDs) in Venezuela including soil-transmitted helminths, ectoparasites and, possibly, vector-borne diseases such as malaria. Additionally, novel experimental evidence has shown that IVM is active and efficacious against Chagas disease, Leishmaniases, arboviruses, and SARS-CoV-2 in vitro. In crisis-hit Venezuela, all of the aforementioned infectious diseases are public health emergencies that have been long ignored and that also require immediate attention. IVM's versatile nature could serve as a powerful tool to tackle the multiple overlapping endemic and emergent diseases that affect Venezuela today. The repurposing of this multipurpose drug would be without a doubt a timely therapeutical approach to help mitigate the tremendous burden of NTDs nationwide."],"journal":"Int J Antimicrob Agents","authors":["Perez-Garcia, Luis A","Mejias-Carpio, Isis E","Delgado-Noguera, Lourdes A","Manzanarez-Motezuma, Jean P","Escalona-Rodriguez, Maria A","Sordillo, Emilia M","Mogollon-Rodriguez, Euler A","Hernandez-Pereira, Carlos E","Marquez-Colmenarez, Marilianna C","Paniz-Mondolfi, Alberto E"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479893","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.ijantimicag.2020.106037","keywords":["ivermectin","venezuela","crisis","endemic","epidemic","humanitarian","multipurpose"],"locations":["Venezuela","Venezuela","Venezuela","Venezuela","Venezuela","Venezuela"],"countries":["Venezuela, Bolivarian Republic of"],"countries_codes":["VEN|Venezuela, Bolivarian Republic of"],"topics":["Treatment"],"weight":1,"_version_":1668437835180408832,"score":9.490897,"similar":[{"pmid":32462282,"title":"Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.","text":["Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.","Ivermectin is an antiparasitic drug that has shown also an effective pharmacological activity towards various infective agents, including viruses. This paper proposes an alternative mechanism of action for this drug that makes it capable of having an antiviral action, also against the novel coronavirus, in addition to the processes already reported in literature.","Naunyn Schmiedebergs Arch Pharmacol","Rizzo, Emanuele","32462282"],"abstract":["Ivermectin is an antiparasitic drug that has shown also an effective pharmacological activity towards various infective agents, including viruses. This paper proposes an alternative mechanism of action for this drug that makes it capable of having an antiviral action, also against the novel coronavirus, in addition to the processes already reported in literature."],"journal":"Naunyn Schmiedebergs Arch Pharmacol","authors":["Rizzo, Emanuele"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462282","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00210-020-01902-5","keywords":["antiviral","covid-19","ionophore","ivermectin","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521475067906,"score":186.8817},{"pmid":32378737,"title":"The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.","text":["The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.","Caly, Druce (1) reported that ivermectin inhibited SARS-CoV-2 in vitro for up to 48 h using ivermectin at 5muM. The concentration resulting in 50% inhibition (IC50, 2 microM) was >35x higher than the maximum plasma concentration (Cmax) after oral administration of the approved dose of ivermectin when given fasted. Simulations were conducted using an available population pharmacokinetic model to predict total (bound and unbound) and unbound plasma concentration-time profiles after a single and repeat fasted administration of the approved dose of ivermectin (200 mug/kg), 60 mg, and 120 mg. Plasma total Cmax was determined and then multiplied by the lung:plasma ratio reported in cattle to predict the lung Cmax after administration of each single dose. Plasma ivermectin concentrations of total (bound and unbound) and unbound concentrations do not reach the IC50 , even for a dose level 10x higher than the approved dose. Even with the high lung:plasma ratio, ivermectin is unlikely to reach the IC50 in lungs after single oral administration of the approved dose (predicted lung: 0.0873 microM) or at doses 10x higher that the approved dose administered orally (predicted lung: 0.820 microM). In summary, the likelihood of a successful clinical trial using the approved dose of ivermectin is low. Combination therapy should be evaluated in vitro. Re-purposing drugs for use in COVID-19 treatment is an ideal strategy but is only feasible when product safety has been established and experiments of re-purposed drugs are conducted at clinically relevant concentrations.","Clin Pharmacol Ther","Schmith, Virginia D","Zhou, Jie Jessie","Lohmer, Lauren Rl","32378737"],"abstract":["Caly, Druce (1) reported that ivermectin inhibited SARS-CoV-2 in vitro for up to 48 h using ivermectin at 5muM. The concentration resulting in 50% inhibition (IC50, 2 microM) was >35x higher than the maximum plasma concentration (Cmax) after oral administration of the approved dose of ivermectin when given fasted. Simulations were conducted using an available population pharmacokinetic model to predict total (bound and unbound) and unbound plasma concentration-time profiles after a single and repeat fasted administration of the approved dose of ivermectin (200 mug/kg), 60 mg, and 120 mg. Plasma total Cmax was determined and then multiplied by the lung:plasma ratio reported in cattle to predict the lung Cmax after administration of each single dose. Plasma ivermectin concentrations of total (bound and unbound) and unbound concentrations do not reach the IC50 , even for a dose level 10x higher than the approved dose. Even with the high lung:plasma ratio, ivermectin is unlikely to reach the IC50 in lungs after single oral administration of the approved dose (predicted lung: 0.0873 microM) or at doses 10x higher that the approved dose administered orally (predicted lung: 0.820 microM). In summary, the likelihood of a successful clinical trial using the approved dose of ivermectin is low. Combination therapy should be evaluated in vitro. Re-purposing drugs for use in COVID-19 treatment is an ideal strategy but is only feasible when product safety has been established and experiments of re-purposed drugs are conducted at clinically relevant concentrations."],"journal":"Clin Pharmacol Ther","authors":["Schmith, Virginia D","Zhou, Jie Jessie","Lohmer, Lauren Rl"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378737","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/cpt.1889","keywords":["covid-19","ivermectin","dose-response","pharmacokinetics"],"locations":["Plasma"],"e_drugs":["Ivermectin"],"topics":["Treatment"],"weight":1,"_version_":1666262687683706880,"score":155.91446},{"pmid":32484155,"title":"Malaria and Parasitic Neglected Tropical Diseases: Potential Syndemics with COVID-19?","text":["Malaria and Parasitic Neglected Tropical Diseases: Potential Syndemics with COVID-19?","The COVID-19 pandemic, caused by SARS-CoV-2, have surpassed 5 million cases globally. Current models suggest that low- and middle-income countries (LMICs) will have a similar incidence but substantially lower mortality rate than high-income countries. However, malaria and neglected tropical diseases (NTDs) are prevalent in LMICs, and coinfections are likely. Both malaria and parasitic NTDs can alter immunologic responses to other infectious agents. Malaria can induce a cytokine storm and pro-coagulant state similar to that seen in severe COVID-19. Consequently, coinfections with malaria parasites and SARS-CoV-2 could result in substantially worse outcomes than mono-infections with either pathogen, and could shift the age pattern of severe COVID-19 to younger age-groups. Enhancing surveillance platforms could provide signals that indicate whether malaria, NTDs, and COVID-19 are syndemics (synergistic epidemics). Based on the prevalence of malaria and NTDs in specific localities, efforts to characterize COVID-19 in LMICs could be expanded by adding testing for malaria and NTDs. Such additional testing would allow the determination of the rates of coinfection and comparison of severity of outcomes by infection status, greatly improving the understanding of the epidemiology of COVID-19 in LMICs and potentially helping to mitigate its impact.","Am J Trop Med Hyg","Gutman, Julie R","Lucchi, Naomi W","Cantey, Paul T","Steinhardt, Laura C","Samuels, Aaron M","Kamb, Mary L","Kapella, Bryan K","McElroy, Peter D","Udhayakumar, Venkatachalam","Lindblade, Kim A","32484155"],"abstract":["The COVID-19 pandemic, caused by SARS-CoV-2, have surpassed 5 million cases globally. Current models suggest that low- and middle-income countries (LMICs) will have a similar incidence but substantially lower mortality rate than high-income countries. However, malaria and neglected tropical diseases (NTDs) are prevalent in LMICs, and coinfections are likely. Both malaria and parasitic NTDs can alter immunologic responses to other infectious agents. Malaria can induce a cytokine storm and pro-coagulant state similar to that seen in severe COVID-19. Consequently, coinfections with malaria parasites and SARS-CoV-2 could result in substantially worse outcomes than mono-infections with either pathogen, and could shift the age pattern of severe COVID-19 to younger age-groups. Enhancing surveillance platforms could provide signals that indicate whether malaria, NTDs, and COVID-19 are syndemics (synergistic epidemics). Based on the prevalence of malaria and NTDs in specific localities, efforts to characterize COVID-19 in LMICs could be expanded by adding testing for malaria and NTDs. Such additional testing would allow the determination of the rates of coinfection and comparison of severity of outcomes by infection status, greatly improving the understanding of the epidemiology of COVID-19 in LMICs and potentially helping to mitigate its impact."],"journal":"Am J Trop Med Hyg","authors":["Gutman, Julie R","Lucchi, Naomi W","Cantey, Paul T","Steinhardt, Laura C","Samuels, Aaron M","Kamb, Mary L","Kapella, Bryan K","McElroy, Peter D","Udhayakumar, Venkatachalam","Lindblade, Kim A"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32484155","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.4269/ajtmh.20-0516","locations":["Malaria","Parasitic"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1668532114799198209,"score":136.10742},{"pmid":32383431,"title":"Novel Coronavirus Disease (COVID-19) Mitigation Steps Provide a Blueprint for Malaria Control and Elimination.","text":["Novel Coronavirus Disease (COVID-19) Mitigation Steps Provide a Blueprint for Malaria Control and Elimination.","Most countries around the world have responded promptly to the novel coronavirus disease (COVID-19) challenge by adopting considered and scientifically guided strategies for its containment. However, the situation is more complex for nations where malaria is endemic, as they now have the additional burden of COVID-19. In such nations, the healthcare systems are either in the preparatory or containment phase of the current pandemic. This enforced, sudden, and sharp public health refocus is likely to result in the disruption of annual malaria control activities such as distribution of insecticide-impregnated bed nets, indoor residual spraying of insecticide, maintenance of malaria surveillance, and mass provision of antimalarial drugs. Nonetheless, we feel that the best facets of COVID-19 public health management can become new guiding principles in malaria-endemic countries to improve malaria control and hasten malaria elimination. Redirection against malaria of the best public health initiatives used in COVID-19 containment could fast-track the global goal of a malaria-free world. Such public health advancement could be one positive outcome from the scourge of COVID-19.","Am J Trop Med Hyg","Rahi, Manju","Das, Payal","Sharma, Amit","32383431"],"abstract":["Most countries around the world have responded promptly to the novel coronavirus disease (COVID-19) challenge by adopting considered and scientifically guided strategies for its containment. However, the situation is more complex for nations where malaria is endemic, as they now have the additional burden of COVID-19. In such nations, the healthcare systems are either in the preparatory or containment phase of the current pandemic. This enforced, sudden, and sharp public health refocus is likely to result in the disruption of annual malaria control activities such as distribution of insecticide-impregnated bed nets, indoor residual spraying of insecticide, maintenance of malaria surveillance, and mass provision of antimalarial drugs. Nonetheless, we feel that the best facets of COVID-19 public health management can become new guiding principles in malaria-endemic countries to improve malaria control and hasten malaria elimination. Redirection against malaria of the best public health initiatives used in COVID-19 containment could fast-track the global goal of a malaria-free world. Such public health advancement could be one positive outcome from the scourge of COVID-19."],"journal":"Am J Trop Med Hyg","authors":["Rahi, Manju","Das, Payal","Sharma, Amit"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383431","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.4269/ajtmh.20-0394","topics":["Prevention"],"weight":1,"_version_":1666267276775522305,"score":122.596375},{"pmid":32450198,"title":"A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic.","text":["A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic.","The chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) have been used as frontline drugs for treatment and prophylaxis against all types of human malaria worldwide. Since late December 2019, humans have been under threat due to an outbreak of a novel coronavirus (SARS-CoV-2) disease (COVID-19; previously known as 2019-nCoV), since its first reported cases in Wuhan, China [1]. Consequently, the virus infection has been declared a pandemic. While the World is finding expedited approvals for the development of vaccine, which is time dependent, being preventative and not possibly a cure, physicians and countries' leaders are considering several concerted clinical trials suggesting that this age-old antimalarial drug, CQ/HCQ could be a potent therapeutic agent against COVID-19 infection. Based on accumulating scientific reports, we have highlighted in this review, the different possible modes of action of chloroquine/hydroxychloroquine that could particularly justify its use against viral infections. Considering the global health crisis of the COVID-19 pandemic, the option of using the drugs and repurposing of old drugs in this instance, chloroquine and hydroxychloroquine, specifically, hydroxychloroquine in the treatment of SARS-CoV-2 could be the best choice. CQ/HCQ has diverse modes of action, like alteration of acidic environment inside lysosome, late endosomes, restriction further with endocytosis, exsosome release, phagolysosomal fusion in systematically and subsequently inhibition of cytokine storm in host cell. One or sum of diverse mechanisms might work against the viral infections and help prevent more deaths. Given that there is no cure for COVID-19, the clinical testing of HCQ is urgently needed to ascertain its potency against the virus as this is the current available treatment option. There is still a need to find other innovative drug candidates as other possible candidate to go into clinical evaluation and testing.","Int J Antimicrob Agents","Tripathy, Satyajit","Dassarma, Barsha","Roy, Somenath","Chabalala, Hlupheka","Matsabisa, Motlalepula Gilbert","32450198"],"abstract":["The chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) have been used as frontline drugs for treatment and prophylaxis against all types of human malaria worldwide. Since late December 2019, humans have been under threat due to an outbreak of a novel coronavirus (SARS-CoV-2) disease (COVID-19; previously known as 2019-nCoV), since its first reported cases in Wuhan, China [1]. Consequently, the virus infection has been declared a pandemic. While the World is finding expedited approvals for the development of vaccine, which is time dependent, being preventative and not possibly a cure, physicians and countries' leaders are considering several concerted clinical trials suggesting that this age-old antimalarial drug, CQ/HCQ could be a potent therapeutic agent against COVID-19 infection. Based on accumulating scientific reports, we have highlighted in this review, the different possible modes of action of chloroquine/hydroxychloroquine that could particularly justify its use against viral infections. Considering the global health crisis of the COVID-19 pandemic, the option of using the drugs and repurposing of old drugs in this instance, chloroquine and hydroxychloroquine, specifically, hydroxychloroquine in the treatment of SARS-CoV-2 could be the best choice. CQ/HCQ has diverse modes of action, like alteration of acidic environment inside lysosome, late endosomes, restriction further with endocytosis, exsosome release, phagolysosomal fusion in systematically and subsequently inhibition of cytokine storm in host cell. One or sum of diverse mechanisms might work against the viral infections and help prevent more deaths. Given that there is no cure for COVID-19, the clinical testing of HCQ is urgently needed to ascertain its potency against the virus as this is the current available treatment option. There is still a need to find other innovative drug candidates as other possible candidate to go into clinical evaluation and testing."],"journal":"Int J Antimicrob Agents","authors":["Tripathy, Satyajit","Dassarma, Barsha","Roy, Somenath","Chabalala, Hlupheka","Matsabisa, Motlalepula Gilbert"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32450198","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.ijantimicag.2020.106028","keywords":["covid-19","chloroquine","hydroxychloroquine","pandemic","sars-cov-2"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667785213921460225,"score":121.54806}]}